CHID1 Variant 2: A Potential Drug Target and Biomarker for Diseases

Target Name: CHID1

NCBI ID: G66005

CHID1

CHID1 Variant 2: A Potential Drug Target and Biomarker for Diseases

CHID1, also known as CHI30, is a protein that is expressed in many tissues throughout the body, including the brain, heart, and lungs. It is a member of the immunoglobulin superfamily and is involved in the development and maintenance of tissues and organs, as well as the regulation of inflammation.

One of the variant forms of CHID1 is CHID1 variant 2, which is a genetic variation that has been identified as a potential drug target. This variant is associated with a variety of immunological and cardiovascular diseases, including autoimmune disorders, neurodegenerative diseases, and cancer.

The exact function of CHID1 variant 2 is not yet fully understood, but it is thought to play a role in the development and progression of these diseases. Studies have shown that CHID1 variant 2 is associated with an increased risk of autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes, as well as neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its association with autoimmune and neurodegenerative diseases, CHID1 variant 2 has also been shown to be involved in the regulation of inflammation. Studies have shown that this variant is expressed at higher levels than the wild-type protein in a variety of tissues and that it is involved in the regulation of inflammation-related processes.

Given its involvement in the development and progression of these diseases, CHID1 variant 2 has potential as a drug target. Researchers are currently studying the effects of drugs that target CHID1 variant 2 in order to determine their effectiveness in treating these diseases.

In addition to its potential as a drug target, CHID1 variant 2 is also an interesting biomarker for a variety of diseases. Studies have shown that CHID1 variant 2 is expressed at higher levels in tissues from individuals with autoimmune disorders and that it is associated with an increased risk of these disorders.

In addition, CHID1 variant 2 has also been shown to be expressed in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that it may be a useful biomarker for these conditions as well.

Overall, CHID1 variant 2 is a protein that is associated with a variety of diseases and conditions, including autoimmune disorders, neurodegenerative diseases, and cancer. Its potential as a drug target and as a biomarker makes it an important area of research for scientists studying these conditions. Further studies are needed to fully understand its role in these diseases and to determine the most effective ways to target it.

Protein Name: Chitinase Domain Containing 1

Functions: Saccharide- and LPS-binding protein with possible roles in pathogen sensing and endotoxin neutralization. Ligand-binding specificity relates to the length of the oligosaccharides, with preference for chitotetraose (in vitro)

The "CHID1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHID1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets